Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML

Area of Science:

• Hematology
• Genetics
• Pediatric Oncology

Background:

• Kostmann's disease (KD) is a rare genetic disorder characterized by severe congenital neutropenia and increased susceptibility to infections.
• Monosomy 7 (Mo7) and leukemia predisposition are known complications associated with KD.
• Recombinant human granulocyte-colony stimulating factor (r-HuG-CSF) therapy improves neutrophil counts and reduces infections in KD patients.

Observation:

• This report details an identical twin with probable autosomal dominant KD undergoing long-term r-HuG-CSF (filgrastim) treatment.
• The patient developed anemia at 18 months, followed by monosomy 7/myelodysplasia (MDS) at 30 months.
• Acute myeloid leukemia (AML) was diagnosed at 50 months of filgrastim treatment.

Findings:

• The development of anemia, Mo7/MDS, and AML in this KD patient occurred sequentially during filgrastim therapy.
• This case raises concerns about a potential association between long-term r-HuG-CSF treatment and the development of secondary hematologic malignancies in KD patients.
• The identical twin's clinical course requires careful monitoring for similar complications.

Implications:

• Further research is crucial to elucidate the natural history of KD and the potential role of filgrastim in its pathobiology.
• This case underscores the need for vigilant monitoring of hematologic parameters in KD patients receiving r-HuG-CSF.
• Understanding this potential link may inform treatment strategies and risk stratification for KD patients.